ClinicalTrials.gg
CompletedNCT03090100ECLIPSEUpdated Oct 1, 2019Results posted

A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis

A Phase 3 interventional study of Guselkumab and Placebo in Psoriasis, sponsored by Janssen Research & Development, LLC. Completed at 142 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-10-01.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,048
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies testing guselkumab in Psoriasis — 8 open to participants now, 9 under way, 1 of them phase 3. guselkumab · Psoriasis.

Enrollment
Largest of 29
1,048 · median 120
Started
2017
with 1 other
Phase 3
12 of 29
none open now
Registered
11th of 29
by date
Lead sponsor
9 of 29
Janssen Research & Development, LLC

Among the 29 studies testing guselkumab in Psoriasis, this one has the largest enrollment, is one of 2 that started in 2017, is one of 12 in phase 3, and was the 11th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

8 of the 29 studies testing guselkumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing guselkumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of guselkumab compared with secukinumab for the treatment of participants with moderate to severe plaque-type psoriasis.

Read the detailed description

The study consists of Screening Phase(4 weeks before administration of study drug),Active Treatment Phase(Week 0-Week 44),Follow Up Phase(Week 44-Week 56).During various study periods,safety assessments(example[e.g] recording of adverse events,Vital signs,Tuberculosis evaluation,Chest radiograph,Urine pregnancy Test);Efficacy assessments(e.g IGA,PASI);Clinical Laboratory Assessments(e.g haematology,chemistry);Biomarkers/Genetic evaluations,will be performed per the study procedures.The primary hypotheses are that guselkumab treatment is non-inferior to secukinumab as assessed by proportion of participants achieving PASI 90 response at Week 48 with noninferiority margin of 10% and,once non-inferiority is established,that guselkumab is superior to secukinumab as assessed by proportion of participants achieving PASI 90 response at Week 48.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of plaque-type psoriasis (with or without [Psoriatic Arthritis]PsA) for at least 6 months before the first administration of study drug
  • A woman of must have a negative urine pregnancy test at screening and at Week 0 and agree to urine pregnancy testing before receiving injections
  • Agree not to receive a live virus or live bacterial vaccination during the study, or within 3 months after the last administration of study drug
  • Agree not to receive a Bacille Calmette-Guérin (BCG) vaccination during the study, or within 12 months after the last administration of study drug
  • Agree to avoid prolonged sun exposure and avoid use of tanning booths or other ultraviolet light sources during study

Exclusion criteria

Exclusion Criteria:

  • Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
  • Has previously received guselkumab or secukinumab
  • Has a history of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection (example bronchiectasis), recurrent urinary tract infection (recurrent pyelonephritis or chronic nonremitting cystitis), fungal infection (mucocutaneous candidiasis), or open, draining, or infected skin wounds or ulcers
  • Has a history of lymphoproliferative disease, including lymphoma; a history of monoclonal gammopathy of undetermined significance; or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy or splenomegaly
  • Is unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access to veins
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,048 participants (actual)

Study arms

  • Experimental
    Group I: Guselkumab Plus Placebo

    Participants will receive 1 injection of active guselkumab and 1 injection of placebo when guselkumab is scheduled to be administered (Weeks 0, 4, 12, 20, 28, 36, and 44) or 2 injections of placebo when no guselkumab is scheduled to be administered (Weeks 1, 2, 3, 8, 16, 24, 32, and 40). Placebo injections will be administered to maintain the blind.

    Drug: Guselkumab · Drug: Placebo

  • Active comparator
    Group II: Secukinumab

    Participants will receive 2 injections of active secukinumab subcutaneously (SC) at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.

    Drug: Secukinumab

Interventions

  • Participants will receive 1 injection of active guselkumab at Weeks 0, 4, 12, 20, 28, 36, and 44.

  • DrugPlacebo

    Participants will receive 1 injection of placebo at Weeks 0, 4, 12, 20, 28, 36, and 44 and 2 injections of placebo at Weeks 1, 2, 3, 8, 16, 24, 32, and 40.

  • Participants will receive 2 injections of active secukinumab at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.

    Also known as: Cosentyx

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 48

    The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants Who Achieved a PASI-75 Response at Both Week 12 and 48

    Percentage of participants who achieved PASI-75 response at both Week 12 and 48 was reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.

    Time frame: Week 12 and 48

  2. Percentage of Participants Who Achieved a PASI-90 Response at Week 12

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline. Due to failing to achieve superiority of prior secondary endpoint, no formal statistical testing was performed for endpoints from this point onwards.

    Time frame: Week 12

  3. Percentage of Participants Who Achieved a PASI-75 Response at Week 12

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.

    Time frame: Week 12

  4. Percentage of Participants Who Achieved a PASI-100 Response at Week 48

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 100 response was defined as 100% reduction in PASI relative to baseline.

    Time frame: Week 48

  5. Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) at Week 48

    The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 48

  6. Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 48

    The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 48

  7. Percentage of Participants Who Achieved a PASI-90 Response at Both Week 16 and 48

    Percentage of participants who achieved PASI-90 response at both Week 16 and 48 was reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline.

    Time frame: Week 16 and 48

  8. Percentage of Participants Who Achieved a PASI-75 Response at Week 16

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.

    Time frame: Week 16

  9. Percentage of Participants Who Achieved a PASI-90 Response at Week 16

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline.

    Time frame: Week 16

  10. Percentage of Participants Who Achieved a PASI-90 Response at All 7 Visits From Week 24 Through Week 48

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline. Percentage of participants who achieved a PASI-90 response at all 7 visits from Week 24 to 48 (Week 24, 28, 32, 36, 40, 44 and 48) was reported.

    Time frame: Week 24 up to Week 48

  11. Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 16

    The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 16

  12. Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 12

    The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 12

  13. Percentage of Participants Who Achieved PASI-75 Response at Week 48 Among PASI-75 Responders at Week 12

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.

    Time frame: Week 48

  14. Percentage of Participants Who Achieved PASI-90 Response at Week 48 Among PASI-90 Responders at Week 16

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90 percent (%) reduction in PASI relative to baseline.

    Time frame: Week 48

  15. Percentage of Participants Who Achieved PASI Response (PASI 100, PASI-90, PASI-75 and PASI-50) Over Time From Week 1 to Week 56

    PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body is divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. PASI produces a numeric score that can range from 0 (no psoriasis) to 72.Participants with \>=50%, \>= 75%, \>=90% and 100% improvement in PASI from baseline were considered PASI 50, 75, 90 and PASI 100 responders, respectively.

    Time frame: Week 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 56

  16. Percentage of Participants With IGA Responses Through Week 56

    The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 56

  17. Percent Improvement From Baseline in PASI Through Week 56

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.

    Time frame: Week 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and Week 56

07

Results

Posted Oct 1, 2019

Participant flow

Participant flow — Overall Study
MilestoneGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Started534514
Treated534511
Completed507466
Not completed2748
Withdrew: Adverse event911
Withdrew: Pregnancy11
Withdrew: Lack of efficacy27
Withdrew: Lost to follow-up22
Withdrew: Withdrawal by subject719
Withdrew: Protocol violation26
Withdrew: Non-compliance20
Withdrew: Other22

Outcome measures

PrimaryPercentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 48

The PASI is a system used for assessing and grading the severity of psoriatic lesions. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas were assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 to 6, and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants who achieved at least a 90 percent improvement from baseline in the PASI score.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 48
Percentage of participantsGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 4884.570.0
Statistical analysis
  • Guselkumab 100 mg + Placebo vs Secukinumab 300 mg · z-test · p = <0.001 · Difference in percentage: 14.2 · 95% CI 9.2 to 19.2
  • Guselkumab 100 mg + Placebo vs Secukinumab 300 mg · Cochran-Mantel-Haenszel · p = <0.001
SecondaryPercentage of Participants Who Achieved a PASI-75 Response at Both Week 12 and 48

Percentage of participants who achieved PASI-75 response at both Week 12 and 48 was reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.

Time frame:
Week 12 and 48
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a PASI-75 Response at Both Week 12 and 48
Percentage of participantsGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Percentage of Participants Who Achieved a PASI-75 Response at Both Week 12 and 4884.680.2
Statistical analysis
  • Guselkumab 100 mg + Placebo vs Secukinumab 300 mg · z-test · p = <0.001 · Difference in percentage: 4.3 · 95% CI -0.2 to 8.9
  • Guselkumab 100 mg + Placebo vs Secukinumab 300 mg · Cochran-Mantel-Haenszel · p = 0.062
SecondaryPercentage of Participants Who Achieved a PASI-90 Response at Week 12

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline. Due to failing to achieve superiority of prior secondary endpoint, no formal statistical testing was performed for endpoints from this point onwards.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a PASI-90 Response at Week 12
Percentage of participantsGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Percentage of Participants Who Achieved a PASI-90 Response at Week 1269.176.1
Statistical analysis
  • Guselkumab 100 mg + Placebo vs Secukinumab 300 mg · Difference in percentage: -7.0 · 95% CI -12.2 to -1.7
SecondaryPercentage of Participants Who Achieved a PASI-75 Response at Week 12

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a PASI-75 Response at Week 12
Percentage of participantsGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Percentage of Participants Who Achieved a PASI-75 Response at Week 1289.391.6
Statistical analysis
  • Guselkumab 100 mg + Placebo vs Secukinumab 300 mg · Difference in percentage: -2.3 · 95% CI -6.0 to 1.2
SecondaryPercentage of Participants Who Achieved a PASI-100 Response at Week 48

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 100 response was defined as 100% reduction in PASI relative to baseline.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a PASI-100 Response at Week 48
Percentage of participantsGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Percentage of Participants Who Achieved a PASI-100 Response at Week 4858.248.4
Statistical analysis
  • Guselkumab 100 mg + Placebo vs Secukinumab 300 mg · Difference in percentage: 9.7 · 95% CI 3.8 to 15.5
SecondaryPercentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) at Week 48

The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) at Week 48
Percentage of participantsGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) at Week 4862.250.4
Statistical analysis
  • Guselkumab 100 mg + Placebo vs Secukinumab 300 mg · Difference in percentage: 11.6 · 95% CI 5.8 to 17.4
SecondaryPercentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 48

The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 48
Percentage of participantsGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 4885.074.9
Statistical analysis
  • Guselkumab 100 mg + Placebo vs Secukinumab 300 mg · Difference in percentage: 9.7 · 95% CI 4.9 to 14.5
SecondaryPercentage of Participants Who Achieved a PASI-90 Response at Both Week 16 and 48

Percentage of participants who achieved PASI-90 response at both Week 16 and 48 was reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline.

Time frame:
Week 16 and 48
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a PASI-90 Response at Both Week 16 and 48
Percentage of participantsGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Percentage of Participants Who Achieved a PASI-90 Response at Both Week 16 and 4872.364.4
Statistical analysis
  • Guselkumab 100 mg + Placebo vs Secukinumab 300 mg · Difference in percentage: 7.8 · 95% CI 2.3 to 13.2
SecondaryPercentage of Participants Who Achieved a PASI-75 Response at Week 16

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a PASI-75 Response at Week 16
Percentage of participantsGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Percentage of Participants Who Achieved a PASI-75 Response at Week 1692.792.8
Statistical analysis
  • Guselkumab 100 mg + Placebo vs Secukinumab 300 mg · Difference in percentage: -0.3 · 95% CI -3.5 to 3.1
SecondaryPercentage of Participants Who Achieved a PASI-90 Response at Week 16

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a PASI-90 Response at Week 16
Percentage of participantsGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Percentage of Participants Who Achieved a PASI-90 Response at Week 1678.579.6
Statistical analysis
  • Guselkumab 100 mg + Placebo vs Secukinumab 300 mg · Difference in percentage: -1.4 · 95% CI -6.2 to 3.4
SecondaryPercentage of Participants Who Achieved a PASI-90 Response at All 7 Visits From Week 24 Through Week 48

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90% reduction in PASI relative to baseline. Percentage of participants who achieved a PASI-90 response at all 7 visits from Week 24 to 48 (Week 24, 28, 32, 36, 40, 44 and 48) was reported.

Time frame:
Week 24 up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved a PASI-90 Response at All 7 Visits From Week 24 Through Week 48
Percentage of participantsGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Percentage of Participants Who Achieved a PASI-90 Response at All 7 Visits From Week 24 Through Week 4871.061.5
Statistical analysis
  • Guselkumab 100 mg + Placebo vs Secukinumab 300 mg · Difference in percentage: 9.8 · 95% CI 4.2 to 15.3
SecondaryPercentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 16

The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 16
Percentage of participantsGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 1686.786.6
Statistical analysis
  • Guselkumab 100 mg + Placebo vs Secukinumab 300 mg · Difference in percentage: -0.1 · 95% CI -4.2 to 3.9
SecondaryPercentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 12

The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 12
Percentage of participantsGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Percentage of Participants With Investigator's Global Assessment (IGA) Score Cleared (0) or Minimal (1) at Week 1285.686.4
Statistical analysis
  • Guselkumab 100 mg + Placebo vs Secukinumab 300 mg · Difference in percentage: -0.9 · 95% CI -5.0 to 3.3
SecondaryPercentage of Participants Who Achieved PASI-75 Response at Week 48 Among PASI-75 Responders at Week 12

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 75 response was defined as at least a 75% reduction in PASI relative to baseline.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved PASI-75 Response at Week 48 Among PASI-75 Responders at Week 12
Percentage of participantsGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Percentage of Participants Who Achieved PASI-75 Response at Week 48 Among PASI-75 Responders at Week 1294.887.5
SecondaryPercentage of Participants Who Achieved PASI-90 Response at Week 48 Among PASI-90 Responders at Week 16

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease. PASI 90 response was defined as at least a 90 percent (%) reduction in PASI relative to baseline.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved PASI-90 Response at Week 48 Among PASI-90 Responders at Week 16
Percentage of participantsGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Percentage of Participants Who Achieved PASI-90 Response at Week 48 Among PASI-90 Responders at Week 1692.180.9
SecondaryPercentage of Participants Who Achieved PASI Response (PASI 100, PASI-90, PASI-75 and PASI-50) Over Time From Week 1 to Week 56

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In PASI system, body is divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. PASI produces a numeric score that can range from 0 (no psoriasis) to 72.Participants with \>=50%, \>= 75%, \>=90% and 100% improvement in PASI from baseline were considered PASI 50, 75, 90 and PASI 100 responders, respectively.

Time frame:
Week 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 56
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved PASI Response (PASI 100, PASI-90, PASI-75 and PASI-50) Over Time From Week 1 to Week 56
Percentage of participantsGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Week 1: 100% improvement00
Week 1: >=90% improvement00
Week 1: >=75% improvement2.11.8
Week 1: >=50% improvement10.712.8
Week 2: 100% improvement0.20.6
Week 2: >=90% improvement1.12.7
Week 2: >=75% improvement6.411.5
Week 2: >=50% improvement30.942.0
Week 3: 100% improvement1.71.6
Week 3: >=90% improvement5.68.6
Week 3: >=75% improvement19.528.4
Week 3: >=50% improvement56.466.9
Week 4: 100% improvement4.15.1
Week 4: >=90% improvement13.121.8
Week 4: >=75% improvement39.350.2
Week 4: >=50% improvement73.485.4
Week 8: 100% improvement20.027.2
Week 8: >=90% improvement48.762.1
Week 8: >=75% improvement76.486.2
Week 8: >=50% improvement95.396.9
Week 12: 100% improvement37.842.0
Week 12: >=90% improvement69.176.1
Week 12: >=75% improvement89.391.6
Week 12: >=50% improvement96.896.1
Week 16: 100% improvement47.846.1
Week 16: >=90% improvement78.579.6
Week 16: >=75% improvement92.792.8
Week 16: >=50% improvement97.696.3
Week 20: 100% improvement51.348.6
Week 20: >=90% improvement80.181.1
Week 20: >=75% improvement93.692.4
Week 20: >=50% improvement97.695.1
Week 24: 100% improvement54.750.4
Week 24: >=90% improvement83.178.2
Week 24: >=75% improvement94.290.3
Week 24: >=50% improvement97.893.0
Week 28: 100% improvement57.151.0
Week 28: >=90% improvement85.477.2
Week 28: >=75% improvement94.090.3
Week 28: >=50% improvement97.293.0
Week 32: 100% improvement57.550.2
Week 32:>=90 % improvement84.877.4
Week 32: >=75% improvement94.089.3
Week 32: >=50% improvement97.093.0
Week 36: 100% improvement58.650.0
Week 36: >=90% improvement84.575.7
Week 36: >=75% improvement93.687.0
Week 36: >=50% improvement97.292.2
Week 40: 100% improvement58.248.6
Week 40: >=90% improvement84.673.7
Week 40: >=75% improvement92.985.8
Week 40: >=50% improvement95.990.9
Week 44: 100% improvement58.649.4
Week 44: >=90% improvement84.172.6
Week 44: >=75% improvement92.385.2
Week 44: >=50% improvement94.291.4
Week 48: 100% improvement58.248.4
Week 48: >=90% improvement84.570.0
Week 48: >=75% improvement92.183.5
Week 48: >=50% improvement94.089.3
Week 56: 100% improvement50.427.0
Week 56: >=90% improvement77.351.4
Week 56: >=75% improvement88.070.4
Week 56: >=50% improvement91.082.1
SecondaryPercentage of Participants With IGA Responses Through Week 56

The IGA documents the investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame:
Week 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 56
Reported as:
Number · Percentage of participants
Percentage of Participants With IGA Responses Through Week 56
Percentage of participantsGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Week 1: cleared (0)00
Week 1: cleared (0) or minimal (1)3.42.5
Week 1: mild or better (=<2)27.234.2
Week 2: cleared (0)0.20.8
Week 2: cleared (0) or minimal (1)12.420.2
Week 2: mild or better (=<2)54.163.8
Week 3: cleared (0)2.63.3
Week 3: cleared (0) or minimal (1)27.239.9
Week 3: mild or better (=<2)75.382.5
Week 4: cleared (0)6.79.7
Week 4: cleared (0) or minimal (1)44.259.3
Week 4: mild or better (=<2)85.692.2
Week 8: cleared (0)29.235.8
Week 8: cleared (0) or minimal (1)76.683.5
Week 8: mild or better (=<2)96.396.3
Week 12: cleared (0)46.350.2
Week 12: cleared (0) or minimal (1)85.686.4
Week 12: mild or better (=<2)96.895.3
Week 16: cleared (0)55.453.5
Week 16: mild or better (=<2)96.894.7
Week 16: cleared (0) or minimal (1)86.786.6
Week 20: cleared (0)56.953.9
Week 20: cleared (0) or minimal (1)87.885.6
Week 20: mild or better (=<2)95.393.2
Week 24: cleared (0)61.056.0
Week 24: cleared (0) or minimal (1)88.682.7
Week 24: mild or better (=<2)96.391.6
Week 28: cleared (0)62.256.2
Week 28: cleared (0) or minimal (1)87.882.9
Week 28: mild or better (<=2)95.590.9
Week 32: cleared (0)63.154.5
Week 32: cleared (0) or minimal (1)88.681.5
Week 32: mild or better (=<2)95.590.5
Week 36: cleared (0)60.753.7
Week 36: cleared (0) or minimal (1)86.579.6
Week 36: mild or better (=<2)95.588.9
Week 40: cleared (0)63.152.3
Week 40: cleared (0) or minimal (1)86.378.0
Week 40: mild or better (=<2)93.687.9
Week 44: cleared (0)62.251.9
Week 44: cleared (0) or minimal (1)86.076.5
Week 44: mild or better (=<2)92.387.5
Week 48: cleared (0)62.250.4
Week 48: cleared (0) or minimal (1)85.074.9
Week 48: mild or better (=<2)92.786.8
Week 56: cleared (0)54.329.4
Week 56: cleared (0) or minimal (1)78.858.2
Week 56: mild or better (=<2)87.576.3
SecondaryPercent Improvement From Baseline in PASI Through Week 56

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.

Time frame:
Week 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and Week 56
Reported as:
Mean · Percent improvement
Percent Improvement From Baseline in PASI Through Week 56
Percent improvementGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Week 120.30 ± 20.74324.72 ± 20.711
Week 237.85 ± 23.56744.56 ± 23.600
Week 352.76 ± 24.18660.57 ± 21.871
Week 464.63 ± 22.86272.80 ± 19.478
Week 884.36 ± 17.27889.40 ± 13.579
Week 1290.85 ± 14.48492.60 ± 13.703
Week 1693.65 ± 12.84993.94 ± 12.123
Week 2094.35 ± 11.52594.41 ± 12.152
Week 2495.27 ± 9.84893.75 ± 14.314
Week 2895.58 ± 9.66392.96 ± 16.835
Week 3295.74 ± 9.33692.95 ± 16.641
Week 3695.45 ± 11.11992.40 ± 17.125
Week 4095.78 ± 10.45691.77 ± 17.733
Week 4495.45 ± 12.29391.34 ± 18.246
Week 4895.76 ± 11.62990.87 ± 19.181
Week 5693.35 ± 16.11681.67 ± 27.627

Adverse events

Collected over Up to Week 56. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Guselkumab 100 mg + Placebo0/534 (0%)33/534 (6.2%)249/534 (46.6%)
Secukinumab 300 mg0/511 (0%)37/511 (7.2%)254/511 (49.7%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventGuselkumab 100 mg + PlaceboSecukinumab 300 mg
Intervertebral Disc ProtrusionMusculoskeletal and connective tissue disorders0/5342/511
Atrial FibrillationCardiac disorders1/5341/511
Atrioventricular Block CompleteCardiac disorders0/5341/511
Cardiac Failure CongestiveCardiac disorders0/5341/511
Crohn's DiseaseGastrointestinal disorders0/5341/511
HaemorrhoidsGastrointestinal disorders0/5341/511
Chest PainGeneral disorders0/5341/511
Exercise Tolerance DecreasedGeneral disorders0/5341/511
Non-Cardiac Chest PainGeneral disorders1/5341/511
CholecystitisHepatobiliary disorders0/5341/511
Most frequent other events
Most frequent other events
EventGuselkumab 100 mg + PlaceboSecukinumab 300 mg
NasopharyngitisInfections and infestations118/534125/511
Upper Respiratory Tract InfectionInfections and infestations83/53492/511
HeadacheNervous system disorders48/53448/511
ArthralgiaMusculoskeletal and connective tissue disorders30/53425/511
Back PainMusculoskeletal and connective tissue disorders29/53418/511
DiarrhoeaGastrointestinal disorders27/53420/511

Baseline characteristics

Full analysis set (FAS) included all participants randomized at Week 0.

Age, Categorical
Age, Categorical(Participants)Guselkumab 100 mg + PlaceboSecukinumab 300 mgTotal
<=18 years628
Between 18 and 65 years474467941
>=65 years544599
Age, Continuous
Age, Continuous(years)Guselkumab 100 mg + PlaceboSecukinumab 300 mgTotal
Mean46.3 ± 13.6745.3 ± 13.5745.8 ± 13.63
Sex: Female, Male
Sex: Female, Male(Participants)Guselkumab 100 mg + PlaceboSecukinumab 300 mgTotal
Female169172341
Male365342707
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Guselkumab 100 mg + PlaceboSecukinumab 300 mgTotal
Hispanic or Latino273663
Not Hispanic or Latino502472974
Unknown or Not Reported5611
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Guselkumab 100 mg + PlaceboSecukinumab 300 mgTotal
American Indian or Alaska Native224
Asian181230
Native Hawaiian or Other Pacific Islander033
Black or African American51116
White499480979
More than one race404
Unknown or Not Reported6612
Region of Enrollment
Region of Enrollment(Participants)Guselkumab 100 mg + PlaceboSecukinumab 300 mgTotal
AUSTRALIA353671
CANADA8177158
CZECH REPUBLIC272855
FRANCE283058
GERMANY6656122
HUNGARY252045
POLAND119119238
SPAIN353368
UNITED STATES118115233
08

Study locations

142 sites
  • University of Alabama Birmingham
    Birmingham, Alabama 35233, United States
  • Southern California Permanente Medical Group
    Los Angeles, California 90027, United States
  • Dermatology Specialists
    Oceanside, California 92056, United States
  • MedDerm Associates
    San Diego, California 92103, United States
  • San Luis Dermatology & Laser Clinic, Inc
    San Luis Obispo, California 93405, United States
  • Southern California Dermatology
    Santa Ana, California 92701, United States
  • Clinical Research Center of Connecticut
    Danbury, Connecticut 06810, United States
  • Olympian Clinical Research
    Clearwater, Florida 33757, United States
  • Florida Academic Dermatology Centers
    Coral Gables, Florida 33134, United States
  • Renstar Medical Research
    Ocala, Florida 34470, United States
  • Park Avenue Dermatology
    Orange Park, Florida 32073, United States
  • Atlanta Dermatology, Vein & Research Center
    Alpharetta, Georgia 30022, United States
  • Advanced Medical Research
    Atlanta, Georgia 30328, United States
  • Marietta Dermatology Clinical Research
    Marietta, Georgia 30060, United States
  • Arlington Dermatology
    Rolling Meadows, Illinois 60008, United States
  • Northshore Universite Healthsystem
    Skokie, Illinois 60077, United States
  • Dawes Fretzin Clinical Research Group
    Indianapolis, Indiana 46256, United States
  • Indiana Clinical Trial Center
    Plainfield, Indiana 46168, United States
  • Dermatology Specialists
    Louisville, Kentucky 40241, United States
  • DermAssociates, PC
    Rockville, Maryland 20850, United States
  • Great Lakes Research Group
    Bay City, Michigan 48706, United States
  • Henry Ford Medical Center
    Detroit, Michigan 49202, United States
  • Hamzavi Dermatology
    Fort Gratiot, Michigan 48059, United States
  • Somerset Skin Centre
    Troy, Michigan 48084, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • Central Dermatology
    Saint Louis, Missouri 63117, United States
  • Windsor Dermatology
    East Windsor, New Jersey 08520-2505, United States
  • Academic Dermatology Associates
    Albuquerque, New Mexico 87106, United States
  • Dermatology Consulting Services, PLLC
    High Point, North Carolina 27262, United States
  • Dermatologists of Greater Columbus
    Bexley, Ohio 43209, United States
  • The Ohio State University
    Gahanna, Ohio 43230, United States
  • Central Sooner Research
    Norman, Oklahoma 73071, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Oregon Medical Research Center
    Portland, Oregon 97223, United States
  • University of Pittsburgh Department of Dermatology
    Pittsburgh, Pennsylvania 15213, United States
  • Clinical Partners
    Johnston, Rhode Island 02919, United States
  • Austin Dermatology Associates
    Austin, Texas 78705, United States
  • Modern Research Associates
    Dallas, Texas 75231, United States
  • Menter Dermatology Research Institute
    Dallas, Texas 75246-1615, United States
  • Suzanne Bruce and Associates - The Center for Skin Research
    Houston, Texas 77056-4132, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
  • Virginia Clinical Research
    Norfolk, Virginia 23322, United States
  • Dermatology Associates of Seattle
    Seattle, Washington 98101-1498, United States
  • The Skin Centre
    Benowa, 4217, Australia
  • Sinclair Dermatology
    East Melbourne, 3002, Australia
  • Fremantle Dermatology
    Fremantle, 6160, Australia
  • Clinical Trials SA Pty Ltd
    Hectorville, 5073, Australia
  • Premier Specialists
    Kogarah, 2217, Australia
  • St George Dermatology & Skin Cancer Centre
    Kogarah, 2217, Australia
  • Skin&Cancer Foundation Inc
    Melbourne, 3053, Australia
  • Royal Melbourne Hospital
    Parkville, 3050, Australia
  • Westmead Hospital
    Westmead, 2145, Australia
  • Woden Dermatology
    Woden, 2606, Australia
  • Veracity Clinical Research
    Woolloongabba, 4102, Australia
  • Dermatrials Research
    Hamilton, Ontario L8N 1Y2, Canada
  • Guenther Dermatology Research Centre
    London, Ontario N6A 3H7, Canada
  • North Bay Dermatology Centre
    North Bay, Ontario P1B 3Z7, Canada
  • Skin Centre for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • Toronto Research Centre
    Toronto, Ontario M3H5Y8, Canada
  • CCA Medical Research Corporation
    Ajax, L1S7K8, Canada
  • Stratica Medical
    Edmonton, T5K 1X3, Canada
  • Eastern Canada Research Associates
    Halifax, B3H 1Z2, Canada
  • DermEdge Research
    Mississauga, L5H 1G9, Canada
  • Innovaderm Research
    Montreal, H2K4L5, Canada
  • Centre Dermatologique
    Quebec, G1V 4X7, Canada
  • Dr. Chih-ho Hong Medical
    Surrey, V3R 6A7, Canada
  • K. Papp Clinical Research
    Waterloo, N2J 1C4, Canada
  • XLR8 Medical Research
    Windsor, N8W 1E6, Canada
  • Nemocnice Jihlava
    Jihlava, 586 33, Czechia
  • Kozni ambulance Kutna Hora, s.r.o.
    Kutna Hora, 248 01, Czechia
  • DERMAMEDICA s.r.o.
    Nachod, 547 01, Czechia
  • Nemocnice Novy Jicin a.s.
    Novy Jicin, 741 01, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava- Poruba, 708 52, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Praha, 775 20, Czechia
  • Dermatologicka ambulance
    Svitavy, 568 02, Czechia
  • Masarykova nemocnice v Usti nad Labem
    Usti Nad Labem, Czechia
  • CHU Bordeaux - Hopital St Andre
    Bordeaux, 33000, France
  • ICH Hopital A. Morvan
    Brest, 29200, France
  • Groupe Hospitalier La Rochelle - Re - Aunis
    La Rochelle, 17019, France
  • Le Bateau Blanc
    Martigues, 13500, France
  • CHU Nantes - Hotel Dieu
    Nantes, 44093, France
  • CHU de Nice Hopital de l Archet
    Nice, 06200, France
  • Hopital Charles Nicolle
    Rouen, 76031, France
  • Hopital Larrey CHU de Toulouse
    Toulouse, 31000, France
  • Charite Universitatsmedizin Berlin, Campus Mitte (CCM) Allergie Center
    Berlin, 10117, Germany
  • ISA GmbH
    Berlin, 10789, Germany
  • Universitatsklinikum Bonn
    Bonn, 53105, Germany
  • Klinische Forschung Dresden GmbH
    Dresden, 01069, Germany
  • University Hospital Dresden
    Dresden, 01307, Germany
  • Universitatsklinikum Essen
    Essen, 45122, Germany
  • Universitatsklinikum Frankfurt
    Frankfurt am Main, 60590, Germany
  • Universitaetsklinik Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • SCIderm GmbH
    Hamburg, 20354, Germany
  • MensingDerma research GmbH
    Hamburg, 22391, Germany
  • Universitatsklinikum Schleswig-Holstein - Kiel
    Kiel, 24105, Germany
  • Universitaetsklinik Luebeck
    Luebeck, 23538, Germany
  • Hautarztpraxis
    Mahlow, 15831, Germany
  • Technische Universitaet Muenchen
    Muenchen, 80802, Germany
  • Universitaetsklinikum Muenster
    Muenster, 48149, Germany

Showing the first 100 of 142 sites across 9 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019 Sep 7;394(10201):831-839. doi: 10.1016/S0140-6736(19)31773-8. Epub 2019 Aug 8. PubMed 31402114 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Aug 2018, 15 months.

Results were first posted in Oct 2019, 1 year 1 month after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 15 months is close to that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2017
First posted
Mar 24, 2017
StartActual
Apr 27, 2017
Primary completionActual
Aug 2, 2018
CompletionActual
Sep 20, 2018
Results first posted
Oct 1, 2019
Last update
Oct 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03090100
Responsible party
Sponsor
First posted
Mar 24, 2017
Start date
Apr 27, 2017
Primary completion
Aug 2, 2018
Completion
Sep 20, 2018
Results posted
Oct 1, 2019
Last update
Oct 1, 2019

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion